GSK opens S$130m facilities in Jurong
New plant and expanded building will step up pharmaceutical firm's output of active ingredients in its HIV medication
Add BT as a preferred source
Singapore
PHARMACEUTICAL giant GlaxoSmithKline (GSK) unveiled a new, fully automated continuous manufacturing facility and an expanded production building at its Jurong site on Friday, worth a total of S$130 million.
The site upgrades will accelerate GSK's global supply chain and, in particular, its production of active pharmaceutical ingredients (APIs) such as Dolutegravir and Lamivudine, key assets in GSK's HIV medication.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
MAS convenes bank CEOs over AI cyberthreats; boards told to own risks, not leave to IT teams
Is it time to scrap COE categories for cars?
